Bernstein, Arthur; Simon, Franklin
August 1958
Angiology;Aug1958, Vol. 9 Issue 4, p197
Academic Journal
Reports on the treatment of cardiovascular symptoms of vasomotor origin by researchers from Newark, New Jersey. Identification on the adverse effects of tranquilizers in the treatment of anxiety; Assessment on the efficacy of the drug in the control of the vasomotor symptomatology; Safety and tolerability of combining three active neurotropic drugs rather than the commonly used brainstem sedative phenobarbital alone in our patients with the psychomotor symptoms.


Related Articles

  • Hamilton Rating Scale for Anxiety (HAM-A). Thompson, Euan // Occupational Medicine;Oct2015, Vol. 65 Issue 7, p601 

    No abstract available.

  • Psychomotor and Anxiolytic Effects of Mexazolam in Patients with Generalised Anxiety Disorder. Ferreira, Luís; Figueira, Maria-Luísa; Bessa-Peixoto, Alberto; Marieiro, António; Albuquerque, Rodolfo; Paz, Cristina; Cerqueira, Ana; Damião, Pedro; Dolgner, Ana; Dingemanse, Jasper // Clinical Drug Investigation;2003, Vol. 23 Issue 4, p235 

    Objective: The primary aim of this study was to evaluate the psychomotor effects of mexazolam versus placebo in patients with generalised anxiety disorder (GAD). Patients and methods: This was a multicentre, randomised, double-blind, parallel-group clinical trial in 60 outpatients with GAD...

  • Effects of Alprazolam on Driving Ability, Memory Functioning and Psychomotor Performance: A Randomized, Placebo-controlled Study. Verster, Joris C.; Volkerts, Edmund R.; Verbaten, Marinus N. // Neuropsychopharmacology;Aug2002, Vol. 27 Issue 2, p260 

    Alprazolam is prescribed for the treatment of anxiety and panic disorder. Most users are presumably involved in daily activities such as driving. However, the effects of alprazolam on driving ability have never been investigated. This study was conducted to determine the effects of alprazolam (1...

  • Pharmacological characterization of stress-induced hyperthermia in DBA/2 mice using metabotropic and ionotropic glutamate receptor ligands. Rorick-Kehn, Linda M.; Hart, John C.; McKinzie, David L. // Psychopharmacology;Dec2005, Vol. 183 Issue 2, p226 

    Rationale: Accumulating evidence suggests that drugs acting on the glutamatergic system may represent promising novel therapeutic targets for the treatment of anxiety disorders. The stress-induced hyperthermia paradigm has been used widely to model some of the physiological symptoms associated...

  • NKP608, an NK[sub 1] receptor antagonist, has an anxiolytic action in the social interaction test in rats. File, Sandra E. // Psychopharmacology;2000, Vol. 152 Issue 1, p105 

    Abstract Rationale: Evidence is starting to accumulate that NK[sub 1] receptor antagonists might have anxiolytic effects in animal tests and in patients. Objective: To examine the effects of NKP608, a substance P antagonist acting at NK[sub 1] receptors, in various conditions of the social...

  • Neuro-pharmacological evaluation of structurally novel 5-hydroxytryptamine type 3 receptor antagonist, N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n) for its anxiolytic potential. Bhatt, Shvetank; Mahesh, Radhakrishnan; Jindal, Ankur; Devadoss, Thangaraj // International Journal of Nutrition, Pharmacology, Neurological D;Oct2013, Vol. 3 Issue 4, p383 

    Aim: The present study was designed to investigate the anxiolytic activity of "N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n)," a novel 5-hydroxytryptamine Type 3 (5-HT3) receptor antagonist in experimental mouse models of anxiety. Materials and Methods: The anxiolytic activity of "6n" (1 and...

  • Antianxiety activity of leaves of Camellia Sinensis. Ashish, Mangal; Vinay, Jain; Jain, Amit; Jat, R. C.; Sudhir, Bharadwaj; Jain, Suman; Subodh, Dubey // Journal of Pharmacy Research;Mar2010, Vol. 3 Issue 3, p605 

    Camellia sinensis is commonly known as green tea, is mainly cultivated in topical and sub topical climate. To the best of our knowledge the plant is so far reported only for memory enhancing properties. In this content we have included neuropharmacological study of camellia sinensis. In this...

  • Cannabis withdrawal: Under-recognized.  // Neurology Alert;Dec2008 Clinical Bri, p24 

    The article discusses research being done on the consequences of marijuana withdrawal. It references a study by D. S. Hasin et al in a 2008 issue of the "American Journal of Psychiatry." Two primary patterns of withdrawal symptoms are commonly reported in frequent marijuana users, namely...

  • Cannabis withdrawal: Under-recognized.  // Infectious Disease Alert;Dec2008 Clinical Briefs in Primary, p24 

    The article discusses research being done on cannabis withdrawal. It references a study by D. S. Hasin et al, published in 2008 issue of "American Journal of Psychiatry." Live interviews were conducted among frequent cannabis users during 2001-2002. Frequent users of the drug commonly reported...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics